Humira Revenue Up 9.6% In U.S., But Down Abroad Due To Biosimilar IN CASE YOU MISSED IT: The poster child for how big, brand-name drug companies abuse the patent system to keep drug prices high continues to reap the benefits from gaming the U.S. patent system. Yesterday, Inside Health Policy reported that Abbvie’s revenue from Humira […]

Continue Reading

Thanks Representatives Spanberger and Reed for introducing legislation to stop the big drug companies from using patent thickets to abuse the patent system and hurt patients WASHINGTON, D.C. – The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others released the following statement today in […]

Continue Reading

IN CASE YOU MISSED IT: A new report from the Kaiser Family Foundation (KFF) examines the rising cost of Medicare Part D drugs and found that Big Pharma has jacked up the price of key prescription drugs well above the rate of inflation between 2016 and 2017. Among the worst offenders, according to the KFF report, are drugs […]

Continue Reading

N CASE YOU MISSED IT: On Wednesday, Law360 published the below op-ed by intellectual property attorneys Stacie Ropka, Ted Mathias, and Chantelle Ankerman. Their op-ed highlights Big Pharma’s use of patent thickets to abuse the patent system and details how drugmaker Abbive has erected patent thickets around its best-selling drug, Humira. Humira was first licensed by the Food and […]

Continue Reading

IN CASE YOU MISSED IT: Yesterday, Axios highlighted a report from the Institute for Clinical and Economic Review (ICER), which found that drugmakers are not raising the prices on their products due to increased quality or safety, but simply because they can. For example, Humira, the world’s best-selling prescription drug, saw a $1.9 billion increase in net spending attributable […]

Continue Reading

IN CASE YOU MISSED IT: Yesterday, STAT News published the below op-ed by Michael Carrier, professor of law at Rutgers Law School and Genevieve Tung, associate director of the Rutgers Law Library. In their op-ed, Carrier, coming off his important testimony last week to the Health Subcommittee of House Committee on Energy & Commerce, and Tung debunk Big Pharma’s disingenuous […]

Continue Reading

IN CASE YOU MISSED IT: Yesterday, Morning Consult published the below op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse. In this must-read piece, Lane praises the ongoing bipartisan efforts of Senators Richard Blumenthal (D-CT) and John Cornyn (R-TX) to rein in Big Pharma’s exploitation of the patent system. However, Lane argues that Congress must […]

Continue Reading

IN CASE YOU MISSED IT: The Washington Examiner published the below op-ed on Friday by Charles Duan, Director of Technology and Innovation Policy at the R Street Institute, examining many ways the STRONGER Patents Act would be disastrous for the patent system, enabling Big Pharma to expand their rampant patent abuse, and for American patients, who will […]

Continue Reading

IN CASE YOU MISSED IT: CNN published the op-ed below today by Lincoln Network co-founder, Garrett Johnson and Innovation Defense Foundation president, Wayne Brough highlighting the importance of inter partes review (IPR) for canceling invalid patents which are a significant cause of the drug pricing crisis facing American patients. This op-ed echoes what CAPA has told lawmakers, that IPR is essential […]

Continue Reading

by Matthew Lane, Coalition Against Patent Abuse American innovation and ingenuity are an essential driver of key medical advancements. They improve countless lives through a myriad of cures and treatments. But with increasingly expensive prescription drug prices and treatments, thanks in no small part to the exploitative behavior of groups like Big Pharma to extend […]

Continue Reading